Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Research and Technology Company Builds off Great Results

Dave Jackson Dave Jackson, Stockhouse
0 Comments| December 24, 2019

{{labelSign}}  Favorites
{{errorMessage}}

CB2 Insights (C.CBII, OTC:CBTOF, Forum) launched as a public company in March 2019 and, against trend in the small cap space, operated with cash flows from operations while growing the company 24 percent year-on-year with Q3 revenues reaching $4.2M.

Recently, oversight bodies such as the FDA began cracking down on medical cannabis providers who claim benefits but have yet to prove safety and efficacy through traditional healthcare channels. The need for real-world evidence is clear and this is where CB2 Insights is set apart from its competitors after five years establishing a strong foundation of technology, data analytical tools and clinical operations.

In this podcast, Stockhouse’s Dave Jackson was joined by the Company’s Chief Executive Officer, Prad Sekar, to discuss CB2’s cutting-edge corporate vision, how it is mainstreaming medical cannabis into traditional healthcare, its cannabis-specific EMR System that’s bringing traditional healthcare protocols to the cannabis industry, and a variety of other industry-related topics.




Listen on Apple PodcastsListen on Google Podcasts



FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today